This company has been marked as potentially delisted and may not be actively trading. Millendo Therapeutics (MLND) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock MLND vs. MBX, AVTE, SBTX, NLTX, CYBN, BIOA, VIRI, WHWK, PYRGF, and OSTXShould you be buying Millendo Therapeutics stock or one of its competitors? The main competitors of Millendo Therapeutics include MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Silverback Therapeutics (SBTX), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), PyroGenesis Canada (PYRGF), and OS Therapies (OSTX). Millendo Therapeutics vs. Its Competitors MBX Biosciences Aerovate Therapeutics Silverback Therapeutics Neoleukin Therapeutics Cybin BioAge Labs Virios Therapeutics Whitehawk Therapeutics PyroGenesis Canada OS Therapies Millendo Therapeutics (NASDAQ:MLND) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation. Does the media refer more to MLND or MBX? In the previous week, MBX Biosciences had 1 more articles in the media than Millendo Therapeutics. MarketBeat recorded 1 mentions for MBX Biosciences and 0 mentions for Millendo Therapeutics. MBX Biosciences' average media sentiment score of 1.16 beat Millendo Therapeutics' score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Millendo Therapeutics Neutral MBX Biosciences Positive Do analysts recommend MLND or MBX? MBX Biosciences has a consensus target price of $37.57, suggesting a potential upside of 173.25%. Given MBX Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe MBX Biosciences is more favorable than Millendo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Millendo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is MLND or MBX more profitable? MBX Biosciences' return on equity of 0.00% beat Millendo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Millendo TherapeuticsN/A -91.03% -72.44% MBX Biosciences N/A N/A N/A Which has stronger valuation & earnings, MLND or MBX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMillendo TherapeuticsN/AN/A-$36.41MN/AN/AMBX BiosciencesN/AN/AN/AN/AN/A SummaryMBX Biosciences beats Millendo Therapeutics on 7 of the 7 factors compared between the two stocks. Get Millendo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MLND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLND vs. The Competition Export to ExcelMetricMillendo TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$142.63M$771.23M$5.49B$9.52BDividend YieldN/A4.84%4.73%4.09%P/E RatioN/A1.3428.7823.81Price / SalesN/A25.68372.2066.04Price / CashN/A19.5635.4557.96Price / Book4.216.768.275.54Net Income-$36.41M-$3.67M$3.25B$259.28M Millendo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLNDMillendo TherapeuticsN/A$7.49+3.6%N/A+322.8%$142.63MN/A0.0012MBXMBX Biosciences2.6586 of 5 stars$14.96+2.8%$37.57+151.1%N/A$500.02MN/A0.0036Positive NewsGap DownAVTEAerovate TherapeuticsN/A$7.75-6.4%N/A-88.5%$224.63MN/A-2.5920High Trading VolumeSBTXSilverback TherapeuticsN/A$18.35+2.7%N/A+68.5%$211.66MN/A-7.5883High Trading VolumeNLTXNeoleukin TherapeuticsN/A$21.68-4.6%N/A-46.3%$203.75MN/A-6.9790CYBNCybin2.5922 of 5 stars$7.57-2.2%$85.00+1,022.9%N/A$178.58MN/A-1.7350BIOABioAge LabsN/A$4.48-1.1%N/AN/A$162.40MN/A0.00N/APositive NewsVIRIVirios TherapeuticsN/A$4.82+1.0%$5.00+3.7%+2,247.1%$92.82MN/A-17.855Upcoming EarningsWHWKWhitehawk TherapeuticsN/A$1.77-2.2%N/AN/A$85.27M$25.98M11.0640Gap UpPYRGFPyroGenesis Canada0.3783 of 5 stars$0.29+0.7%N/A-53.5%$54.23M$9.14M-4.8390News CoverageGap UpHigh Trading VolumeOSTXOS Therapies2.1009 of 5 stars$1.83+1.7%$18.00+883.6%N/A$51.42MN/A-2.13N/A Related Companies and Tools Related Companies MBX Alternatives AVTE Alternatives SBTX Alternatives NLTX Alternatives CYBN Alternatives BIOA Alternatives VIRI Alternatives WHWK Alternatives PYRGF Alternatives OSTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLND) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Millendo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Millendo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
